Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dragonfly Therapeutics Appoints Head of Biologics | Contract Pharma
Promotions & Moves

Dragonfly Therapeutics Appoints Head of Biologics

Grinberg brings track record of scientific accomplishments and creativity in protein-based drug development

Dr. Asya Grinberg has been appointed head of biologics at Dragonfly Therapeutics, and joins the senior team. Dr. Grinberg will lead the protein engineering, purification, characterization and structural biology team.
 
Dr. Grinberg joins the company from Acceleron Pharma, where she led a multidisciplinary team in cell biology and protein chemistry. She most recently served as senior director of Cell Biology and Protein Chemistry and has been a strong scientific and strategic driver of internal innovation. Dr. Grinberg’s efforts were instrumental to the development of five clinical candidates, including Luspatercept (in Phase III testing) for treatment of beta-thalassemia and MDS.  Dr. Grinberg is the key inventor of the IntelliTrap drug discovery platform targeting the TGF-beta superfamily.
 
“We are thrilled to welcome Dr. Grinberg to Dragonfly,” said Dragonfly co-founder and chief executive officer Bill Haney. “Her depth of understanding of protein therapeutics, coupled with her talent for innovation, will accelerate our development of novel cancer therapies, which use Natural Killer cells to both enhance the effectiveness of T cell performance and attack cancer directly.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters